, Volume 215, Issue 3, pp 527–536 | Cite as

MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study

  • Andrew C. ParrottEmail author
  • Amy Gibbs
  • Andrew B. Scholey
  • Rebecca King
  • Katherine Owens
  • Phil Swann
  • Ed Ogden
  • Con Stough
Original Investigation



This study investigated the acute mood effects of oral MDMA, methamphetamine, and placebo in a double-blind laboratory study.


Fifty-two healthy participants comprised abstinent recreational users of stimulant drugs, 27 female and 25 male, mean age 24.8 years. Three test sessions involved acute 100 mg oral 3.4-methylendioxymethamphetamine (MDMA), 0.42 mg/kg oral methamphetamine, and matching placebo. Drug administration was counterbalanced, testing was double-blind, and medical supervision was present throughout. Car-driving performance on a laboratory simulator was assessed after 3 and 24 h, with the findings being presented elsewhere. Positive and negative moods (PANAS self-ratings) were completed before drug administration, 3, 4.5, and 24 h later. Blood samples were taken to monitor drug plasma levels.


Following MDMA, there were no significant increases in positive moods, whereas negative moods were significantly higher than under placebo. Methamphetamine led to significant increases in both positive and negative moods. The MDMA findings contrast with the elated moods, typically noted by dance clubbers on Ecstasy. However, they are consistent with some previous laboratory findings, since a wide array of positive and negative mood changes have been demonstrated. One possible explanatory factor was the neutral environmental situation, particularly if a primary action of MDMA is to intensify ongoing psychological states. Other explanatory factors, such as dosage, gender, post-drug timing, neurohormonal aspects, and social factors, are also discussed.


In the laboratory, acute methamphetamine led to significantly higher positive moods. However, against expectations, MDMA did not generate a significant increase in positive moods.


MDMA Ecstasy Methamphetamine Mood Environment PANAS Serotonin Dopamine 



This study was funded by an Australian Research Council Grant to Professors Con Stough, Papafotiou and Vic Ogden: grant DP0772762. Professor Andy Parrott was on sabbatical at the Brain Science Institute, Swinburne University, partially funded by NIDA grant DA-14910.


  1. Baylen CA, Rosenberg N (2006) A review of the acute subjective effects of MDMA/ecstasy. Addiction 101:933–994PubMedCrossRefGoogle Scholar
  2. Bedi G, de Wit H (2011). Individual differences in acute responses to MDMA in humans: effects of sex and past ecstasy use. Open Addiction Journal (in press)Google Scholar
  3. Bedi G, Phan KL, Angstadt M, de Wit H (2009) Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology 207:73–83PubMedCrossRefGoogle Scholar
  4. Bedi G, Hyman D, de Wit H (2010) Is ecstasy an empathogen? Effects of 3, 4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry 68:1134–1140PubMedCrossRefGoogle Scholar
  5. Cadet JL, Krasnova IN, Jayanthi S, Lyles J (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11:183–202PubMedCrossRefGoogle Scholar
  6. Cami J, Farré M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3, 4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455–466PubMedCrossRefGoogle Scholar
  7. Clemens KJ, McGregor IS, Hunt GE, Cornish JL (2007) MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. Drug Alcohol Rev 26:9–15PubMedCrossRefGoogle Scholar
  8. Cohen RS (1998) The love drug: marching to the beat of ecstasy. Haworth Medical Press, New York StateGoogle Scholar
  9. Comer SD, Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001) Effects of repeated oral methamphetamine administration in humans. Psychopharmacology 155:397–404PubMedCrossRefGoogle Scholar
  10. Cruickshank CC, Dyer KR (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104:1085–1099PubMedCrossRefGoogle Scholar
  11. Davison D, Parrott AC (1997) Ecstasy in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 12:91–97CrossRefGoogle Scholar
  12. Degenhardt L, Hall W (2009). The health and psychological effects of “ecstasy” (MDMA) use. NDARC monograph, no. 62. University of New South Wales, AustraliaGoogle Scholar
  13. Dumont GJ, Verkes RJ (2006) A review of acute effects of 3, 4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20:176–187PubMedCrossRefGoogle Scholar
  14. Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, van Gerven JM, Buitelaar JK, Verkes RJ (2009) Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3, 4-methylenedioxymethamphetamine) administration. Soc Neurosci 4:359–366PubMedCrossRefGoogle Scholar
  15. Dumont GJ, Schoemaker RC, Touw DJ, Sweep FC, Buitelaar JK, van Gerven JM, Verkes RJ (2010) Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. J Psychopharmacol 24:155–164PubMedCrossRefGoogle Scholar
  16. Farré M, de la Torre R, Mathúna BO, Roset PN, Peiró AM, Torrens M, Ortuño J, Pujadas M, Camí J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology 173:364–375PubMedCrossRefGoogle Scholar
  17. Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 55:463–508PubMedCrossRefGoogle Scholar
  18. Greer G, Tolbert R (1990). The therapeutic use of MDMA. The clinical, pharmacological and neurotoxicological effects of the drug MDMA. Peroutka SJ (ed.). Kluwer, New YorkGoogle Scholar
  19. Greer G, Tolbert R (1986). Subjective reports of the effects of MDMA in a clinical setting. J Psychoact Drugs 18:319–327Google Scholar
  20. Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001) Methamphetamine self-administration by humans. Psychopharmacology 157:75–81PubMedCrossRefGoogle Scholar
  21. Hart CL, Gunderson EW, Perez A, Kirkpatrick MG, Thurmond A, Comer SD et al (2008) Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 33:1847–1855PubMedCrossRefGoogle Scholar
  22. Hernández-López C, Farré M, Roset PN, Menoyo E, Pizarro N, Ortuño J, Torrens M, Camí J, de La Torre R (2002) 3, 4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300:236–244PubMedCrossRefGoogle Scholar
  23. Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, White JM (2006) Plasma drug concentrations and physiological measures in ‘dance party’ participants. Neuropsychopharmacology 31:424–430PubMedCrossRefGoogle Scholar
  24. Iversen L (2006) Speed, ecstasy, ritalin: the science of the amphetamines. Oxford University Press, OxfordGoogle Scholar
  25. Johanson CE, Kilbey M, Gatchalian K, Tancer M (2006) Discriminative stimulus effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81:27–36PubMedCrossRefGoogle Scholar
  26. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Physiological and subjective responses to controlled oral 3, 4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28:432–440PubMedCrossRefGoogle Scholar
  27. Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154:161–168PubMedCrossRefGoogle Scholar
  28. Lynch WJ, Roth ME, Carroll ME (2002) Biological basis of sex differences in drug abuse: pre-clinical and clinical studies. Psychopharmacology 164:121–137PubMedCrossRefGoogle Scholar
  29. M ter Bogt TF, Engels RC (2005) "Partying" hard: party style, motives for and effects of MDMA use at rave parties. Subst Use Misuse 40:1479–1502PubMedCrossRefGoogle Scholar
  30. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology 173:434–439PubMedCrossRefGoogle Scholar
  31. McGregor IS, Callaghan PD, Hunt GE (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use? Br J Pharmacol 154:358–368PubMedCrossRefGoogle Scholar
  32. Mendelson J, Uemura N, Harris D, Nath RP, Fernandez E, Jacob P, Everhart ET, Jones RT (2006) Human pharmacology of the methamphetamine stereoisomers. Clin Pharmacol Ther 80:403–420PubMedCrossRefGoogle Scholar
  33. Murphy PN, Wareing M, Fisk JE, Montgomery C (2009) Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review. Neuropsychobiology 60:159–175PubMedCrossRefGoogle Scholar
  34. Papafotiou K, Carter JD, Stough C (2005) The relationship between performance on the standardised field sobriety tests, driving performance and the level of Delta9-tetrahydrocannabinol (THC) in blood. Forensic Sci Int 155:172–178PubMedCrossRefGoogle Scholar
  35. Parrott AC (1994) Individual differences in stress and arousal during cigarette smoking. Psychopharmacology 115:389–396PubMedCrossRefGoogle Scholar
  36. Parrott AC (1999) Does cigarette smoking cause stress? Am Psychol 54:817–820PubMedCrossRefGoogle Scholar
  37. Parrott AC (2001) Human psychopharmacology of Ecstasy (MDMA): a review of fifteen years of empirical research. Hum Psychopharmacol 16:557–577PubMedCrossRefGoogle Scholar
  38. Parrott AC (2002) Recreational MDMA (Ecstasy), the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837–844PubMedCrossRefGoogle Scholar
  39. Parrott AC (2004a) Is Ecstasy MDMA ? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology 173:234–241PubMedCrossRefGoogle Scholar
  40. Parrott AC (2004b) MDMA (3, 4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50:329–335PubMedCrossRefGoogle Scholar
  41. Parrott AC (2005) Chronic tolerance to recreational MDMA (3, 4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19:71–83PubMedCrossRefGoogle Scholar
  42. Parrott AC (2006) MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. J Psychopharmacol 20:147–163PubMedCrossRefGoogle Scholar
  43. Parrott AC (2009) Cortisol and MDMA: neurohormonal aspects of bioenergetic stress in Ecstasy users. Neuropsychobiology 60:148–158PubMedCrossRefGoogle Scholar
  44. Parrott AC (2010) Conscious awareness versus optimistic beliefs in recreational Ecstasy/MDMA users. In: Perry E, Collerton D, LeBeau F, Ashton HE (eds) New horizons in the neuroscience of consciousness. John Benjamins Publishers, AmsterdamGoogle Scholar
  45. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 139:261–268PubMedCrossRefGoogle Scholar
  46. Parrott AC, Lock J, Conner AC, Kissling C, Thome J (2008) Dance clubbing on-MDMA and during abstinence from MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 57:165–180PubMedCrossRefGoogle Scholar
  47. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3, 4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273–277PubMedGoogle Scholar
  48. Scholey AB, Parrott AC, Buchanan T, Heffernan T, Ling J, Rodgers J (2004) Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a www study. Addict Behav 29:743–752PubMedCrossRefGoogle Scholar
  49. Scholey AB, Owen L, Gates J, Rodgers J, Buchanan T, Ling J, Heffernan T, Swan P, Stough C, Parrott AC (2010) Hair MDMA samples are consistent with reported Ecstasy use: findings from a study investigating effects of Ecstasy on mood and memory. Neuropsychobiology 63:15–21PubMedCrossRefGoogle Scholar
  50. Silber BY, Croft RJ, Papafotiou K, Stough C (2006) The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology 187(1):54–169Google Scholar
  51. Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of ecstasy users and their experiences with the drug. Br J Addict 87:1161–1172PubMedCrossRefGoogle Scholar
  52. Tancer ME, Johanson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65:97–101PubMedCrossRefGoogle Scholar
  53. Tancer ME, Johanson CE (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72:33–44PubMedCrossRefGoogle Scholar
  54. Tancer M, Johanson CE (2007) The effects of fluoxetine on the subjective and physiological effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189:565–573PubMedCrossRefGoogle Scholar
  55. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55:105–115PubMedCrossRefGoogle Scholar
  56. Verheyden SL, Henry JA, Curran HV (2003) Acute, sub-acute and long-term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users. Hum Psychopharmacol 18:507–517PubMedCrossRefGoogle Scholar
  57. Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063–1070PubMedCrossRefGoogle Scholar
  58. White TL, Lott DC, de Wit H (2006) Personality and the subjective effects of acute amphetamine in healthy volunteers. Neuropsychopharmacology 31:1064–1074PubMedCrossRefGoogle Scholar
  59. Yacoubian GS, Boyle C, Harding CA, Loftus EA (2003) It’s a rave new world: estimating the prevalence and perceived harm of ecstasy and other drug use among club rave attendees. J Drug Educ 33:187–196PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Andrew C. Parrott
    • 1
    • 3
    Email author
  • Amy Gibbs
    • 1
  • Andrew B. Scholey
    • 1
  • Rebecca King
    • 1
  • Katherine Owens
    • 1
  • Phil Swann
    • 1
  • Ed Ogden
    • 2
  • Con Stough
    • 1
  1. 1.Brain Sciences InstituteSwinburne UniversityMelbourneAustralia
  2. 2.Vicroads, Victorian Government, KewMelbourneAustralia
  3. 3.Department of PsychologySwansea UniversitySwanseaUK

Personalised recommendations